Premium
Raloxifene, a New Selective Estrogen Receptor Modulator
Author(s) -
Goldfrank Deborah,
Haytoglu Tahir,
Frishman William H.,
Mohammad Zalt
Publication year - 1999
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/00912709922008416
Subject(s) - raloxifene , selective estrogen receptor modulator , estrogen , tamoxifen , medicine , osteoporosis , endocrinology , estrogen receptor , hormone replacement therapy (female to male) , breast cancer , cancer , testosterone (patch)
There is evidence from observational studies that estrogen replacement therapy in postmenopausal women can reduce the rates of morbidity and mortality of atherosclerotic heart disease. The mechanism of this cardiovascular protective effect is not yet established, but favorable actions of hormone therapy on plasma lipids and vascular endothelial function have been proposed. Estrogens can also increase the risk of breast and uterine carcinoma. The new selective estrogen receptor modulator (SERM) raloxifene appears to have benefits similar to estrogen on plasma lipids and osteoporosis, but it does not affect the rate of uterine carcinoma as does tamoxifen and estrogen. Animal studies suggest an anti‐atherosclerotic action of raloxifene, but this needs to be confirmed in long‐term human studies.